Clinical trial · Observational
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey
NCT02669771CI-TRIAL-00082834completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| enzalutamide | Drug | Enzalutamide | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Enzalutamide group
- description
- oral
- interventionNames
- Drug: enzalutamide
Primary outcomes (1)
- measure
- Incidences of Adverse Events
- timeFrame
- Up to 2 years
Secondary outcomes (2)
- measure
- Overall Survival
- timeFrame
- Up to 2 years
- measure
- Change from baseline in PSA value
- timeFrame
- Up to 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * no history of treatment with enzalutamide Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.